Pharmacia & Upjohn reboxetine
Executive Summary
NDA for antidepressant reboxetine submitted to FDA April 29. Submission includes data on 900 patients with major depressive disorders from one long-term and two short-term trials. Selective norepinephrine reuptake inhibitor has been marketed in the U.K. since July as Edronax